According to Clarivate data, China is now the world's largest producer and exporter of APIs, providing about 30% of the world's API production capacity. According to the preliminary statistics of the China Chamber of Commerce for Import and Export of Medicines and Health Products in May 2021, the export scale of my country's API industry has exceeded 35 billion US dollars in 2020.

As the "chip" assets of medicine, APIs have been paid more and more attention. Consistency evaluation puts quality first and improves the status of APIs. In the context of centralized procurement, the decline in the price of preparations has brought about an increase in the penetration rate, accelerated the volume of APIs, and at the same time, centralized procurement has weakened the position of sales in the industry chain. The cost advantage of API enterprises has been enlarged, and the space for the integration of API preparations has been opened.